Slide 1: Full year and fourth quarter 2022 results
Q4 Full year and fourth quarter 2022 results Audiocast presentation 14 February 2023
Slide 2: Forward looking statements
2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-lo
Slide 3: Agenda
3 Agenda • Transformative 2022 Company participants • Fourth quarter achievements Fredrik Tiberg, PhD • Financial performance and President & CEO, CSO outlook 2023 Jon Garay Alonso Chief Financial Officer • Commercial development Richard Jameson • R&D pipeline update Chief Commercial Officer • Expec
Slide 4: Successful 2022 for Camurus
4 Successful 2022 for Camurus Total revenue MSEK 1000 •Entered profitability with strong revenue growth 800 +59% ‒ Double digit FY revenue growth to close to one billion SEK 600 ‒ Positive cashflow and FY profitable – ahead of plan 400 ‒ Investing half a billion SEK in the R&D pipeline 200 •Commerci
Slide 5: Strong fourth quarter performance
5 Strong fourth quarter performance •High growth and positive result Total revenue ‒ Double-digit QoQ revenue growth SEK 268 million ‒ Fourth consecutive quarter with positive operating result +47% vs Q4 2021 •Market expansion Operating result ‒ First Buvidal orders in Egypt and Saudi Arabia ‒ Brixa
Slide 6: Enhanced sustainability framework
6 Enhanced sustainability framework Updated sustainability strategy implemented – Considering ESG throughout business execution – Strategy implemented based on UN SDGs with long term goals and KPIs – All employees trained on sustainability policy Strengthened sustainability management Sustainability
Slide 7: Financial performance
camurus. Financial performance
Slide 8: Reported Quarter profit and loss and FY 2022
8 Reported Quarter profit and loss and FY 2022 CER CER MSEK Oct – Dec Change Change Jan – Dec Change Change 2022 vs. 2021 vs. 2021 2022 vs. 2021 vs. 2021 Total revenues 268 +47% +36% 956 +59% +50% Gross margin 240 +496bps +506bps 853 +341bps +294bps OPEX 223 +28% +24% 789 +26% +20% Other Operating I
Slide 9: Strong cash generation – no debt
9 Strong cash generation – no debt •Continued improvement in cash flow from operations and working capital MSEK Capital allocation priorities 566 • Reinvest in our business: ‒ Buvidal market penetration & geographical expansion ‒ CAM2029 development to market 520 • Synergistic inorganic growth oppor
Slide 10: Outlook 2023
10 Outlook 2023 •Key factors •Full year 2023 guidance •Top line revenue •Revenue • Increased governmental austerity •SEK 1,530 – 1,650 million* measures + 60 – 73% vs. 2022 • Addressing market access hurdles •Profit before taxes Strategic investments •SEK 425 – 525 million* • R&D investments to driv
Slide 11: Commercial development
camurus. Commercial development
Slide 12: Continued Buvidal market performance
12 Continued Buvidal market performance •Solid sales growth •Quarterly product sales ‒ Net sales was SEK 267 million; +57% YoY, +11% QoQ MSEK • In-market sales growth of 16% QoQ in Europe 300 • Largest contribution from Australia, Nordics, and UK 267 • Highest growth rate in Belgium, Spain, Austria,
Slide 13: Positive developments in the US
13 Positive developments in the US •Brixadi1 NDA resubmitted by Braeburn •Brixadi well differentiated and positioned3 NDA resubmission 23 November 2022 LAI features NDA acceptance with PDUFA date of 23 May 2023 Weekly dosing – – NDA approval decision Monthly dosing Brixadi launch by
Slide 14: R&D pipeline update
camurus. R&D pipeline update
Slide 15: Octreotide SC depot
15 Octreotide SC depot CAM2029 under assessment in three serious rare-disease indications • Acromegaly • Gastroenteropancreatic neuroendocrine tumors (GEP-NET) • Polycystic liver disease (PLD) •Designed for enhanced efficacy and patient convenience
Slide 16: CAM2029 Phase 3 programs advancing
16 CAM2029 Phase 3 programs advancing NDA/MAA Phase 3 RCT approval decisions ACRO est. NDA/MAA Phase 3 LST Trial extension approval decisions NET est. GEP-NET Phase 3 RCT PLD Phase 2b RCT Phase 3 continuation Prefilled pen PK bridge -2022 2023 2024 2025 2026 ACRO Phase 3 RCT ACRO Phase 3 LST GEP-NET
Slide 17: CAM2029 clinical trials status update
17 CAM2029 clinical trials status update Pivotal randomized placebo controlled Subcutaneous Octreotide Randomized Polycystic liver Safety and efficacy and long-term safety trials in acromegaly Efficacy in Neuroendocrine TumOrs TriAl with subcutaneous Octreotide Two Phase 3 trials ongoing SORENTO
Slide 18: Ongoing preparations for launches of CAM2029
18 Ongoing preparations for launches of CAM2029 •Manufacturing •Planned scientific conferences Commercial manufacturing process established Q1 2023 Q2 2023 Q3 2023 Q4 2023 Process validation completed Global ASCO-GI AACE2023 ENDO NANETS Stability studies for submissions ongoing 17-21 Jan San F
Slide 19: Large market potential for CAM2029
19 Large market potential for CAM2029 •Attractive opportunity GlobalData report5 ‒ Block buster potential in NET ‒ Highly concentrated target audiences ‒ Differentiated product features ‒ Switch opportunity from established first-line treatments • CAM2029 peak sales estimates from third party market
Slide 20: Key take aways from a strong fourth quarter 2022
20 Key take aways from a strong fourth quarter 2022 Commercialization execution R&D pipeline advancement Corporate development Continued strong Buvidal sales Brixadi™ NDA accepted by FDA Profitability reached for the third growth and penetration across with 23 May 2023 PDUFA date consecutive q
Slide 21: Expected key milestones in 2023
21 Expected key milestones in 2023 •Commercialization Buvidal market expansion through new regulatory and market access approvals US approval and launch of Brixadi in opioid dependence •Advancing the pipeline Topline Phase 3 efficacy results in acromegaly First readout Phase 3 long-term safe
Slide 22: Q&A
camurus. O&A
Slide 23: Experienced and committed management team
23 Experienced and committed management team Fredrik Tiberg, PhD Education: M.Sc. in Chem. Eng., Lund Institute of Technology, Jon Garay Alonso Education: Bachelor in Business Administration by President & CEO, CSO PhD and Assoc. Prof. Physical Chemistry, Lund University. Chief Financial Officer Uni
Slide 24: Shareholders and analyst coverage
24 Shareholders and analyst coverage Shareholders as of 31 January 2023 Number of shares % of capital % of votes Sandberg Development AB 21,875,692 39.5 39.5 Fjärde AP-fonden 3,070,571 5.5 5.5 Analysts Didner & Gerge Fonder 2,286,697 4.1 4.1 Carnegie Avanza Pension 2,031,874 3.7 3.7 Erik Hultgård Fr